Ascendis Pharma A/S (ASND) |
| 215.05 6.29 (3.01%) 01-13 16:00 |
| Open: | 209 |
| High: | 221.75 |
| Low: | 206 |
| Volume: | 1,282,098 |
| Market Cap: | 12,959(M) |
| PE Ratio: | -48.11 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 268.57 |
| Resistance 1: | 229.94 |
| Pivot price: | 210.57 |
| Support 1: | 204.07 |
| Support 2: | 188.08 |
| 52w High: | 229.94 |
| 52w Low: | 118.03 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Financials
| EPS | -4.480 |
| Book Value | -3.350 |
| PEG Ratio | 0.00 |
| Gross Profit | 9.185 |
| Profit Margin (%) | -36.03 |
| Operating Margin (%) | 5.15 |
| Return on Assets (ttm) | -7.7 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 13 Jan 2026
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $246 - 富途牛牛
Mon, 12 Jan 2026
Ascendis Pharma A/S Touts €683M Product Revenue, Feb PDUFA Catalyst at JPM Healthcare Conference - Yahoo Finance
Mon, 12 Jan 2026
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders - Yahoo Finance
Mon, 12 Jan 2026
Ascendis Pharma A/S (ASND) Stock Analysis: A 29.8% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Mon, 12 Jan 2026
Ascendis Pharma Sets 2026 Milestones and Unveils $120 Million Share Buyback - TipRanks
Fri, 09 Jan 2026
Ascendis Pharma (ASND) Focuses on Core Plans Amidst Market Condi - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
